A recent scientific review has explored the potential of cannabinoid anti-tumor effects across various cancer types, including glioblastoma and breast cancer. The comprehensive meta-analysis of preclinical trial data suggests that certain cannabis components may exhibit “consistent and statistically significant anti-tumor effects” and could potentially enhance the efficacy of chemotherapy agents, according to Marijuana Moment.
Published in the journal Pharmaceuticals, this research was conducted by scientists at Semmelweis University and the University of Pécs. They described their work as providing “the most comprehensive systematic synthesis to date of preclinical evidence regarding the antitumor effects of cannabinoids across a wide spectrum of cancer models.”
Preclinical Evidence for Cannabinoid Anti-Tumor Effects
The review indicated that cannabis compounds show promise as supplementary treatments in oncology, particularly for glioblastoma and breast cancer. Researchers observed that cannabinoids “demonstrated consistent and statistically significant antitumor effects” in preclinical models of these cancers, with additional supportive evidence noted for lung and prostate cancer. Glioblastoma, an aggressive form of brain cancer, emerged as the tumor type with the most reproducible evidence base in this analysis.
Among the cannabinoids examined, cannabidiol (CBD), a non-intoxicating compound, appeared to have the “broadest and most favorable profile.” This was attributed to its consistent anti-tumor activity and a well-documented safety record in clinical use. In animal models of glioblastoma, cannabinoid therapy was associated with a notable reduction in tumor volume, averaging -980.58 mm³ compared to control groups. Similarly, in breast cancer models, cannabinoids were linked to an average tumor volume decrease of -402.64 mm³.
Cannabinoids and Chemotherapy Efficacy
The review also investigated the potential for cannabinoids to enhance the effectiveness of chemotherapy. When combined with the chemotherapy medication doxorubicin in preclinical breast cancer models, cannabinoids were associated with an average tumor volume decrease of -1295.19 mm³ compared to doxorubicin administered alone. This finding suggests a synergistic potential that warrants further investigation.
However, the researchers emphasised the importance of caution, stating that “not all combinations are beneficial and that rigorous preclinical screening is required before clinical translation.” They also noted that tetrahydrocannabinol (THC) “produced highly variable effects,” suggesting that the therapeutic benefits of cannabinoid therapies may not be universal and depend on the specific cannabinoid and cancer type.
Broader Context and Future Directions in Research
This review contributes to a growing body of scientific literature exploring the potential of cannabinoids in cancer care. Other recent systematic reviews have similarly concluded that studies “consistently show” CBD as a potential anti-cancer agent across various cancer types, including those affecting both humans and animals. These investigations have explored CBD’s impact on aggressive cancers such as glioblastoma, as well as its potential to influence the growth and metastasis of breast, lung, colorectal, ovarian, and prostate cancers.
As previously reported by Hemp Gazette, building on earlier coverage of cannabinoids and chemotherapy, a paper published in the journal Pharmacology & Therapeutics also assessed clinical and preclinical findings suggesting that medical cannabis could enhance the efficacy of chemotherapy drugs. While current evidence is largely preclinical, these findings underscore the need for continued, well-designed clinical trials to understand the full potential and appropriate application of cannabinoid therapies in cancer treatment pathways.
Patients with cancer using medical cannabis have also reported experiencing significant improvements in cancer-related symptoms, according to a separate study. This patient-reported evidence, alongside preclinical findings, highlights the ongoing need for robust clinical research to integrate cannabinoid therapies safely and effectively into conventional oncology practices.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
